New Ways to Derisk and Accelerate Dermal Drug Development

Only one out of 24 dermal drug candidates reaches the market. The key reason for development failure is often a lack of information on drug availability and the drug‘s mode of action in the skin. This leads to expensive late-stage clinical trial failures and ultimately to delayed patient benefits.

dOFM is a sampling technology that enables continuous monitoring of pharmacokinetics and pharmacodynamics of drugs in skin tissue. This webinar presents preclinical dOFM models and early clinical pilot studies that can be used to provide crucial information predicting the outcome of a main clinical study. The effectiveness of this approach will be demonstrated by presenting selected case studies that illustrate the predictive power of dOFM results for the clinical efficacy of drugs in development. The ability of gaining such insights at the early phase of drug product development is a key factor for pharma companies to follow a „Win Quick Fail Fast” strategy.

Speakers:

Thomas Birngruber, PhD

Wen-Kai Hsiao, PhD

Please register your interest in attending this webinar via ofm@joanneum.at so they can forward you reminders and the session link when it becomes available.